ATCC Number:CRL-1878?
是否是腫瘤細(xì)胞:0
物種來源:褐鼠
數(shù)量:大量
運(yùn)輸方式:凍存運(yùn)輸
細(xì)胞形態(tài):淋巴樣
免疫類型:IgG2b
生長狀態(tài):懸浮生長
規(guī)格:0.5mg Designations: YN1/1.7.4
Depositors: ?F Takei
Isotype: IgG2b
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Rattus norvegicus (B cell); Rattus norvegicus (myeloma) deposited as rat (B cell); rat (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against murine ICAM-1 (ICAM 1, intercellular adhesion molecule)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with NS-1 mouse myeloma cells.
Spleen cells were fused with Y3 rat myeloma cells.
The antibody reacts with a 95000 to 100000 dalton antigen (ICAM-1) on activated and proliferating murine lymphocytes.
The antibody partially inhibits Con A stimulation of spleen cells but does not inhibit LPS stimulation.
The antibody strongly inhibits mixed lymphocyte responses (MLR).
The ICAM-1 antigen is absent on most unstimulated thymocytes and spleen cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
References: 1776: Takei F. Inhibition of mixed lymphocyte response by a rat monoclonal antibody to a novel murine lymphocyte activation antigen (MALA-2). J. Immunol. 134: 1403-1407, 1985. PubMed: 2981916